Back to Search
Start Over
Effect of OM-85 BV on reducing bronchiectasis exacerbation in Chinese patients: the iPROBE study
- Source :
- J Thorac Dis
- Publication Year :
- 2021
- Publisher :
- AME Publishing Company, 2021.
-
Abstract
- Background Bronchiectasis is characterized by recurrent infectious exacerbations. No existing data inform preventive strategy for exacerbations beyond chronic macrolides. OM-85 BV, an immunostimulant, has been shown to prevent recurrent respiratory infections. We initiated this 1-year, multi-centered, double-blind, and controlled trial to investigate the PReventive effect of OM-85 BV on Bronchiectasis Exacerbations in Chinese patients (iPROBE). Methods Patients with bronchiectasis aged 18 to 75 years, having at least one exacerbation in the past year, were randomized to receive, in addition to any respiratory medications, two courses of 7 mg of OM-85 BV or matching placebo (one capsule orally per day for 10 days a month) for 3 consecutive months, followed by 3 months without treatment. The primary outcomes included the number of acute infectious exacerbations and the time to first exacerbation. Secondary endpoints included patient-reported respiratory outcomes. Safety measures were also assessed. Results Among the 196 participants, 99 were in the OM-85 BV group and 97 in the placebo group. At week 52, the mean number of acute exacerbations per patient was equal to 0.98 and 0.75, respectively, in the two groups (P=0.14). Difference in the time to first pulmonary exacerbation was not statistically significant (P=0.11). There was no statistically significant difference in any secondary end-points. The safety profile in the two arms was good and the majority of adverse events were mild. Conclusions OM-85 BV did not demonstrate protection in decreasing pulmonary exacerbations of bronchiectasis in this trial performed in Chinese patients. It had good safety profile.
- Subjects :
- Pulmonary and Respiratory Medicine
medicine.medical_specialty
Bronchiectasis
Exacerbation
business.industry
medicine.disease
Placebo
Placebo group
law.invention
03 medical and health sciences
0302 clinical medicine
030228 respiratory system
Randomized controlled trial
law
Internal medicine
medicine
Original Article
030212 general & internal medicine
Respiratory system
business
Adverse effect
Pulmonary exacerbation
Subjects
Details
- ISSN :
- 20776624 and 20721439
- Volume :
- 13
- Database :
- OpenAIRE
- Journal :
- Journal of Thoracic Disease
- Accession number :
- edsair.doi.dedup.....65c0a148658d422e7398d7895b3d93d9